Suppr超能文献

细胞因子信号转导抑制因子1(SOCS1)及其假定的肿瘤抑制功能下游靶点在前列腺癌中的表达

Expression of SOCS1 and the downstream targets of its putative tumor suppressor functions in prostate cancer.

作者信息

Chevrier Martin, Bobbala Diwakar, Villalobos-Hernandez Alberto, Khan Md Gulam Musawwir, Ramanathan Sheela, Saucier Caroline, Ferbeyre Gerardo, Geha Sameh, Ilangumaran Subburaj

机构信息

Department of Pathology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Canada.

Department of Pediatrics, Immunology division, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Canada.

出版信息

BMC Cancer. 2017 Feb 24;17(1):157. doi: 10.1186/s12885-017-3141-8.

Abstract

BACKGROUND

Suppressor of cytokine signaling 1 (SOCS1) is considered a tumor suppressor due to frequent epigenetic and micro-RNA-mediated repression of its gene expression in diverse cancers. In prostate cancer (PCa), elevated expression of miR-30d that targets SOCS1 mRNA is associated with increased risk of disease recurrence. SOCS1 can mediate its tumor suppressor functions by diverse mechanisms such as inhibiting the JAK-STAT signaling pathway, promoting the tumor suppressor functions of p53, attenuating MET receptor tyrosine kinase signaling and blocking the oncogenic potential of the cell cycle inhibitor p21 (p21). Here, we studied the expression of SOCS1 and the downstream targets of its putative tumor suppressor functions (p53, MET and p21) in human PCa specimens to evaluate their significance as markers of disease prognosis.

METHODS

Tissue microarrays were constructed of 78 archived prostatectomy specimens that were grouped according to the recommendations of the International Society of Urological Pathology (ISUP) based on the Gleason patterns. SOCS1, p53, MET and p21 protein expression were evaluated by immunohistochemical staining alongside the common prostate cancer-related markers Ki67, prostein and androgen receptor. Statistical correlations between the staining intensities of these markers and ISUP grade groups, local invasion or lymph node metastasis were evaluated.

RESULTS

SOCS1 showed diffuse staining in the prostatic epithelium. SOCS1 staining intensity correlated inversely with the ISUP grade groups (ρ = -0.4687, p <0.0001) and Ki67 (ρ = -0.2444, p = 0.031), and positively with prostein (ρ = 0.3511, p = 0.0016). Changes in SOCS1 levels did not significantly associate with those of p53, MET or p21. However, p21 positively correlated with androgen receptor expression (ρ = -0.1388, p = 0.0003). A subset of patients with regional lymph node metastasis, although small in number, showed reduced SOCS1 expression and increased expression of MET and p21.

CONCLUSIONS

Our findings suggest that evaluating SOCS1 and p21 protein expression in prostatectomy specimens may have a prognostic value in identifying the aggressive disease. Hence, prospective studies with larger numbers of metastatic PCa specimens incorporating clinical correlates such as disease-free and overall survival are warranted.

摘要

背景

细胞因子信号转导抑制因子1(SOCS1)被认为是一种肿瘤抑制因子,因为在多种癌症中其基因表达经常受到表观遗传和微小RNA介导的抑制。在前列腺癌(PCa)中,靶向SOCS1 mRNA的miR-30d表达升高与疾病复发风险增加相关。SOCS1可通过多种机制介导其肿瘤抑制功能,如抑制JAK-STAT信号通路、促进p53的肿瘤抑制功能、减弱MET受体酪氨酸激酶信号传导以及阻断细胞周期抑制剂p21(p21)的致癌潜能。在此,我们研究了人PCa标本中SOCS1及其假定的肿瘤抑制功能的下游靶点(p53、MET和p21)的表达,以评估它们作为疾病预后标志物的意义。

方法

用78份存档的前列腺切除标本构建组织微阵列,这些标本根据国际泌尿病理学会(ISUP)的建议基于Gleason模式进行分组。通过免疫组织化学染色评估SOCS1、p53、MET和p21蛋白表达,同时评估常见的前列腺癌相关标志物Ki67、前列腺素和雄激素受体。评估这些标志物的染色强度与ISUP分级组、局部浸润或淋巴结转移之间的统计相关性。

结果

SOCS1在前列腺上皮中呈弥漫性染色。SOCS1染色强度与ISUP分级组呈负相关(ρ = -0.4687,p <0.0001),与Ki67呈负相关(ρ = -0.2444,p = 0.031),与前列腺素呈正相关(ρ = 0.3511,p = 0.0016)。SOCS1水平的变化与p53、MET或p21的水平无显著相关性。然而,p21与雄激素受体表达呈正相关(ρ = -0.1388,p = 0.0003)。一部分区域淋巴结转移患者,尽管数量较少,但显示出SOCS1表达降低以及MET和p21表达增加。

结论

我们的研究结果表明,评估前列腺切除标本中SOCS1和p21蛋白表达可能对识别侵袭性疾病具有预后价值。因此,有必要对更多转移性PCa标本进行前瞻性研究,并纳入无病生存期和总生存期等临床相关指标。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/498d/5326496/8e7d4eeb7bdd/12885_2017_3141_Fig1_HTML.jpg

相似文献

3
SOCS1 inhibits migration and invasion of prostate cancer cells, attenuates tumor growth and modulates the tumor stroma.
Prostate Cancer Prostatic Dis. 2017 Mar;20(1):36-47. doi: 10.1038/pcan.2016.50. Epub 2016 Oct 25.
7
Regulation of MET receptor tyrosine kinase signaling by suppressor of cytokine signaling 1 in hepatocellular carcinoma.
Oncogene. 2015 Nov 12;34(46):5718-28. doi: 10.1038/onc.2015.20. Epub 2015 Mar 2.
8
Identification of miR-30d as a novel prognostic maker of prostate cancer.
Oncotarget. 2012 Nov;3(11):1455-71. doi: 10.18632/oncotarget.696.
9
Tumour-promoting role of SOCS1 in colorectal cancer cells.
Sci Rep. 2015 Sep 22;5:14301. doi: 10.1038/srep14301.

引用本文的文献

1
MKI67 with arterial hypertension predict a poor survival for prostate cancer patients, a real-life investigation.
Clin Transl Oncol. 2024 Dec;26(12):3037-3049. doi: 10.1007/s12094-024-03505-5. Epub 2024 May 24.
2
Unraveling the complexity of STAT3 in cancer: molecular understanding and drug discovery.
J Exp Clin Cancer Res. 2024 Jan 20;43(1):23. doi: 10.1186/s13046-024-02949-5.
6
Functional annotation of noncoding mutations in cancer.
Life Sci Alliance. 2021 Jul 19;4(9). doi: 10.26508/lsa.201900523. Print 2021 Sep.
7
Walnut polyphenol extracts inhibit -induced STAT3 phosphorylation through activation of PPAR-γ and SOCS1 induction.
J Clin Biochem Nutr. 2020 Nov;67(3):248-256. doi: 10.3164/jcbn.20-89. Epub 2020 Sep 30.
8
STAT3 and STAT5 Activation in Solid Cancers.
Cancers (Basel). 2019 Sep 25;11(10):1428. doi: 10.3390/cancers11101428.
9
Radiotherapy resistance acquisition in Glioblastoma. Role of SOCS1 and SOCS3.
PLoS One. 2019 Feb 27;14(2):e0212581. doi: 10.1371/journal.pone.0212581. eCollection 2019.
10
Exosomes of pasteurized milk: potential pathogens of Western diseases.
J Transl Med. 2019 Jan 3;17(1):3. doi: 10.1186/s12967-018-1760-8.

本文引用的文献

1
SOCS1 inhibits migration and invasion of prostate cancer cells, attenuates tumor growth and modulates the tumor stroma.
Prostate Cancer Prostatic Dis. 2017 Mar;20(1):36-47. doi: 10.1038/pcan.2016.50. Epub 2016 Oct 25.
2
p21 shapes cancer evolution.
Nat Cell Biol. 2016 Jun 28;18(7):722-4. doi: 10.1038/ncb3382.
3
The molecular and cellular origin of human prostate cancer.
Biochim Biophys Acta. 2016 Jun;1863(6 Pt A):1238-60. doi: 10.1016/j.bbamcr.2016.02.016. Epub 2016 Feb 26.
4
The importance of non-nuclear AR signaling in prostate cancer progression and therapeutic resistance.
Cell Signal. 2016 May;28(5):348-356. doi: 10.1016/j.cellsig.2016.01.013. Epub 2016 Jan 29.
5
AR-V7 and prostate cancer: The watershed for treatment selection?
Cancer Treat Rev. 2016 Feb;43:27-35. doi: 10.1016/j.ctrv.2015.12.003. Epub 2015 Dec 18.
7
Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer.
Nat Rev Cancer. 2015 Dec;15(12):701-11. doi: 10.1038/nrc4016. Epub 2015 Nov 13.
9
Androgen receptor profiling predicts prostate cancer outcome.
EMBO Mol Med. 2015 Nov;7(11):1450-64. doi: 10.15252/emmm.201505424.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验